{"id":"NCT00960869","sponsor":"POZEN","briefTitle":"Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","officialTitle":"A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2012-02","completion":"2012-02","firstPosted":"2009-08-18","resultsPosted":"2016-02-17","lastUpdate":"2016-02-17"},"enrollment":519,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Ulcer"],"interventions":[{"type":"DRUG","name":"PA32540","otherNames":["YOSPRALA"]},{"type":"DRUG","name":"EC-Aspirin 325 mg","otherNames":[]}],"arms":[{"label":"PA32540","type":"EXPERIMENTAL"},{"label":"EC-Aspirin 325 mg","type":"ACTIVE_COMPARATOR"}],"summary":"Primary: To demonstrate that PA32540 causes fewer gastric ulcers in subjects at risk for developing aspirin-associated gastric ulcers compared to enteric coated (EC) aspirin 325 mg.","primaryOutcome":{"measure":"Number of Participants With Gastric Ulcer Confirmed by Endoscopy","timeFrame":"6 months","effectByArm":[{"arm":"PA32540","deltaMin":7,"sd":null},{"arm":"EC-Aspirin 325 mg","deltaMin":22,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"}]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":257},"commonTop":["Dyspepsia","Gastritis erosive","Gastritis","Hiatus hernia","Oesophagitis"]}}